转移性乳腺癌患者治疗指导中的成本节约潜力。
Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
作者信息
Robertson J F, Whynes D K, Dixon A, Blamey R W
机构信息
Department of Surgery, City Hospital, Nottingham, UK.
出版信息
Br J Cancer. 1995 Jul;72(1):174-7. doi: 10.1038/bjc.1995.297.
Abstract
Therapeutic response in patients with advanced breast cancer is conventionally assessed with reference to criteria devised by the International Union Against Cancer. Evidence to date suggests, however, that assessments of equivalent quality may be obtained at lower cost from the use of serum markers. The paper presents estimates of potential cost savings resulting from the use of serum markers in place of conventional assessment and argues that the size of these savings merits the establishment of a randomised controlled trial.
摘要
晚期乳腺癌患者的治疗反应通常参照国际抗癌联盟制定的标准进行评估。然而，迄今为止的证据表明，使用血清标志物可以以更低的成本获得同等质量的评估。本文给出了使用血清标志物替代传统评估可能节省的成本估计，并认为这些节省的规模值得开展一项随机对照试验。
相似文献
1
Potential for cost economies in guiding therapy in patients with metastatic breast cancer.转移性乳腺癌患者治疗指导中的成本节约潜力。
Br J Cancer. 1995 Jul;72(1):174-7. doi: 10.1038/bjc.1995.297.
2
Economic analysis of psychosocial group therapy in women with metastatic breast cancer.转移性乳腺癌女性心理社会团体治疗的经济分析
Breast Cancer Res Treat. 2006 Nov;100(2):183-90. doi: 10.1007/s10549-006-9249-1. Epub 2006 Jun 14.
3
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.从加拿大医疗保健系统的角度比较，曲妥珠单抗恩美曲妥珠单抗与卡培他滨加拉帕替尼治疗HER2阳性局部晚期或转移性乳腺癌相关不良事件的安全性和成本。
Clin Drug Investig. 2015 Aug;35(8):487-93. doi: 10.1007/s40261-015-0302-x.
4
Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.自体骨髓移植的成本效益使用：答案寥寥，问题众多，以及对未来评估的建议。
Pharmacoeconomics. 1994 Aug;6(2):114-26. doi: 10.2165/00019053-199406020-00004.
5
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.HER-2检测与曲妥珠单抗治疗转移性乳腺癌的成本效益分析
J Clin Oncol. 2004 Mar 1;22(5):854-63. doi: 10.1200/JCO.2004.04.158.
6
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.使用生物标志物指导转移性乳腺癌女性全身治疗决策：美国临床肿瘤学会临床实践指南
J Clin Oncol. 2015 Aug 20;33(24):2695-704. doi: 10.1200/JCO.2015.61.1459. Epub 2015 Jul 20.
7
Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer.早期乳腺癌保乳术后基于证据的放射治疗方法的成本影响
J Oncol Pract. 2017 Apr;13(4):e283-e290. doi: 10.1200/JOP.2016.016683. Epub 2017 Mar 14.
8
Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important.晚期乳腺癌的预后结果：无转移间期很重要。
Hum Pathol. 2017 Dec;70:70-76. doi: 10.1016/j.humpath.2017.10.002. Epub 2017 Oct 13.
9
Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
Minerva Chir. 2003 Jun;58(3):297-303.
10
[Cost-Effectiveness of the 21 Gene Assay in Patients with Node-Positive Breast Cancer].[21基因检测在淋巴结阳性乳腺癌患者中的成本效益分析]
Gesundheitswesen. 2016 Nov;78(11):772-780. doi: 10.1055/s-0035-1549989. Epub 2015 Jun 24.
引用本文的文献
1
Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis.血浆热休克蛋白90α1预测乳腺癌发病及远处转移风险。
Front Cell Dev Biol. 2021 May 24;9:639596. doi: 10.3389/fcell.2021.639596. eCollection 2021.
2
Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.预测三阴性乳腺癌患者治疗前CA15-3和CEA血清水平预后价值的列线图
PLoS One. 2016 Aug 25;11(8):e0161902. doi: 10.1371/journal.pone.0161902. eCollection 2016.
3
Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients.通过对原发性乳腺癌患者进行CA 15.3的系列测量来预测症状性转移
J Res Med Sci. 2012 Sep;17(9):850-4.
4
Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.乳腺癌复发事件的治疗医疗费用：基于英国患者层面分析的估计
Br J Cancer. 2007 Aug 20;97(4):479-85. doi: 10.1038/sj.bjc.6603887. Epub 2007 Jul 24.
本文引用的文献
1
Advanced breast cancer: use of resources and cost implications.晚期乳腺癌：资源利用及成本影响
Br J Cancer. 1993 Apr;67(4):856-60. doi: 10.1038/bjc.1993.157.
2
Chemotherapy of advanced breast cancer: outcome and prognostic factors.晚期乳腺癌的化疗：治疗结果与预后因素
Br J Cancer. 1993 Nov;68(5):988-95. doi: 10.1038/bjc.1993.467.
3
4
Long-chain aliphatic fatty acids and phytanic acid simultaneously measured by dual-column capillary chromatography.采用双柱毛细管色谱法同时测定长链脂肪酸和植烷酸。
Clin Chem. 1989 Sep;35(9):1989-91.
5
An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer.乳腺癌中黏蛋白样癌相关抗原（MCA）的评估。
Br J Cancer. 1989 May;59(5):797-800. doi: 10.1038/bjc.1989.166.
6
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.预测晚期乳腺癌患者对内分泌（甲地孕酮）治疗反应的因素。
Eur J Cancer Clin Oncol. 1989 Mar;25(3):469-75. doi: 10.1016/0277-5379(89)90259-9.
7
Assessment of four monoclonal antibodies as serum markers in breast cancer.评估四种单克隆抗体作为乳腺癌血清标志物的情况。
Eur J Cancer. 1990;26(11-12):1127-32. doi: 10.1016/0277-5379(90)90268-x.
8
An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data.转移性乳腺癌治疗反应的客观生化评估：一项对临床数据进行外部审查的研究
Br J Cancer. 1990 Jan;61(1):126-32. doi: 10.1038/bjc.1990.26.
9
Use of mucin like cancer associated antigen (MCA) in the management of breast cancer.黏蛋白样癌相关抗原（MCA）在乳腺癌治疗中的应用。
Br J Cancer. 1991 Jun;63(6):1000-4. doi: 10.1038/bjc.1991.217.
10
Objective measurement of therapeutic response in breast cancer using tumour markers.使用肿瘤标志物客观测量乳腺癌的治疗反应。
Br J Cancer. 1991 Oct;64(4):757-63. doi: 10.1038/bjc.1991.394.
Zotero 插件